Fundraising FoxLupeng Pharmaceutical
3 known investors
Find your way into Lupeng Pharmaceutical
Sign up to find every way you can get introduced to Lupeng Pharmaceutical
- Your email: who you already know at Lupeng Pharmaceutical, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Lupeng Pharmaceutical team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.
Founders & leadership
周
周正清首席财务官 (CFO)
SA
Stephen Anthony首席医学官 (Chief Medical Officer)
Investors · 3
Frequently asked questions
- What does Lupeng Pharmaceutical do?
- Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets. Its lead drug rocbrutinib (Lukeda) has received NMPA approval for market in China.
- Who are Lupeng Pharmaceutical's investors?
- Lupeng Pharmaceutical's investors include LAV, Lilly Asia Ventures, OrbiMed.